Prevymis (letermovir) - Merck (MSD)
MISP CMV: Letermovir for R+ Study (clinicaltrials.gov) - Jul 16, 2026 - P4 | N=146 | Not yet recruiting | Sponsor: University of Wisconsin, Madison 
New P4 trial • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation
http://clinicaltrials.gov/ct2/show/NCT07706166
 
Jul 16, 2026
 
Prev Next